KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aquestive Therapeutics (AQST) Gross Profit (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Gross Profit data on record, last reported at $17.8 million in Q4 2025.

  • For Q4 2025, Gross Profit rose 1515.08% year-over-year to $17.8 million; the TTM value through Dec 2025 reached $38.8 million, down 2.22%, while the annual FY2025 figure was $38.8 million, 2.22% down from the prior year.
  • Gross Profit reached $17.8 million in Q4 2025 per AQST's latest filing, up from $8.3 million in the prior quarter.
  • Across five years, Gross Profit topped out at $24.8 million in Q4 2022 and bottomed at -$2.5 million in Q2 2021.
  • Average Gross Profit over 5 years is $9.0 million, with a median of $7.9 million recorded in 2022.
  • Peak YoY movement for Gross Profit: crashed 85.75% in 2024, then surged 1515.08% in 2025.
  • A 5-year view of Gross Profit shows it stood at $7.7 million in 2021, then skyrocketed by 221.1% to $24.8 million in 2022, then tumbled by 68.81% to $7.7 million in 2023, then plummeted by 85.75% to $1.1 million in 2024, then soared by 1515.08% to $17.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $17.8 million in Q4 2025, $8.3 million in Q3 2025, and $5.4 million in Q2 2025.